Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2026-05-21 Proxy Solicitation & In…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad anuncia la convocatoria de la Junta General Ordinaria de Accionistas y remite propuestas de acuerdos.
Proxy Solicitation & Information Statement Classification · 92% confidence The document is an official notice convening Pharma Mar’s Ordinary General Shareholders’ Meeting (“Junta General Ordinaria de Accionistas”), including the agenda, proposed resolutions, proxy and voting instructions, and related meeting materials. It is not the AGM presentation itself nor the meeting minutes or results, but the solicitation and information statement sent to shareholders to inform them and request their votes. This corresponds to Proxy Solicitation & Information Statement (PSI).
2026-05-21 Spanish
La Sociedad anuncia la convocatoria de la Junta General Ordinaria de Accionistas y remite propuestas de acuerdos.
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal ‘‘anuncio de convocatoria’’ of the Annual General Shareholders’ Meeting (Junta General Ordinaria) of Pharma Mar, including the meeting date, agenda items, proposals to be voted on, and detailed proxy voting instructions. It is not the AGM materials themselves, nor the voting results; rather, it is the proxy solicitation and information statement sent to shareholders to inform them and solicit their votes. This corresponds to the Proxy Solicitation & Information Statement category (PSI).
2026-05-21 Spanish
La Sociedad publica información financiera correspondiente al primer trimestre de 2026.
Earnings Release Classification · 95% confidence The document is a press release titled “Nota de prensa” presenting the group's first quarter 2026 financial results, with key metrics (revenues, EBITDA, net income, cash, debt) and highlights. It is not a full interim report but an initial announcement of quarterly results. Therefore, it fits the Earnings Release category (ER). Q1 2026
2026-04-29 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 98% confidence The document is a CNMV “Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities” (PDMR) detailing share purchases by the company’s director. This is a classic insider trading disclosure by a director, matching the Director’s Dealing category.
2026-04-22 Spanish
Las autoridades sanitarias de Australia y Singapur aprueban la combinación de Zepzelca® (lurbinectedina) de PharmaMar y atezolizumab (Tecentriq®) en primera línea de mantenimiento para cáncer de pulmó
Regulatory Filings Classification · 88% confidence The document is a corporate press release filed with the Spanish securities regulator (CNMV) under Article 227 (“Other Relevant Information”). It provides drug regulatory approval updates, not financial results, manager changes, voting outcomes, or detailed investor materials. It does not fit any other specific category, so it falls into the generic “Regulatory Filings” (RNS) fallback category.
2026-04-20 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 95% confidence The document is a Spanish CNMV standard form titled “Standard form for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.” It details share transactions by a PDMR (Inés Pérez Calleja), including acquisitions and sales of Pharma Mar, S.A. shares. This matches the definition of Director’s Dealing (report of personal share transactions by company directors and executives).
2026-04-10 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.